Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Covishield in Liver Cirrhosis
NCT04794946Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Open-label trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoints: Proportion of patients with presence of antibodies titres at 6 months and Safety and tolerability profile at 6 months. Status: unknown.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04794946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794946.